Global Circulating Biomarker for Liquid Biopsy Market Research Report 2023

Publication ID:

PB503237707

Publication Date:

March 22, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Highlights
The global Circulating Biomarker for Liquid Biopsy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Circulating Biomarker for Liquid Biopsy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Circulating Biomarker for Liquid Biopsy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Circulating Biomarker for Liquid Biopsy in Early Cancer Screening is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Circulating Biomarker for Liquid Biopsy include Abbott Laboratories, Becton, Dickinson and Company, GE Healthcare, Epigenomics AG, Agilent Technologies, Biocept, Affymetrix and Fluxion Biosciences, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Circulating Biomarker for Liquid Biopsy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Biomarker for Liquid Biopsy.
The Circulating Biomarker for Liquid Biopsy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Circulating Biomarker for Liquid Biopsy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Circulating Biomarker for Liquid Biopsy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Abbott Laboratories
Becton, Dickinson and Company
GE Healthcare
Epigenomics AG
Agilent Technologies
Biocept
Affymetrix
Fluxion Biosciences
Segment by Type
Circulating Tumor Cells (CTCs)
Circulating Tumor DNA (ctDNA)
Cell-Free DNA (cfDNA)
Extracellular Vesicles (EVs)
Others
Segment by Application
Early Cancer Screening
Therapy Selection
Treatment Monitoring
Recurrence Monitoring Orthopedics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Circulating Biomarker for Liquid Biopsy companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Circulating Biomarker for Liquid Biopsy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Circulating Tumor Cells (CTCs)
1.2.3 Circulating Tumor DNA (ctDNA)
1.2.4 Cell-Free DNA (cfDNA)
1.2.5 Extracellular Vesicles (EVs)
1.2.6 Others
1.3 Market by Application
1.3.1 Global Circulating Biomarker for Liquid Biopsy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Early Cancer Screening
1.3.3 Therapy Selection
1.3.4 Treatment Monitoring
1.3.5 Recurrence Monitoring Orthopedics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Circulating Biomarker for Liquid Biopsy Market Perspective (2018-2029)
2.2 Circulating Biomarker for Liquid Biopsy Growth Trends by Region
2.2.1 Global Circulating Biomarker for Liquid Biopsy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Circulating Biomarker for Liquid Biopsy Historic Market Size by Region (2018-2023)
2.2.3 Circulating Biomarker for Liquid Biopsy Forecasted Market Size by Region (2024-2029)
2.3 Circulating Biomarker for Liquid Biopsy Market Dynamics
2.3.1 Circulating Biomarker for Liquid Biopsy Industry Trends
2.3.2 Circulating Biomarker for Liquid Biopsy Market Drivers
2.3.3 Circulating Biomarker for Liquid Biopsy Market Challenges
2.3.4 Circulating Biomarker for Liquid Biopsy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Circulating Biomarker for Liquid Biopsy Players by Revenue
3.1.1 Global Top Circulating Biomarker for Liquid Biopsy Players by Revenue (2018-2023)
3.1.2 Global Circulating Biomarker for Liquid Biopsy Revenue Market Share by Players (2018-2023)
3.2 Global Circulating Biomarker for Liquid Biopsy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Circulating Biomarker for Liquid Biopsy Revenue
3.4 Global Circulating Biomarker for Liquid Biopsy Market Concentration Ratio
3.4.1 Global Circulating Biomarker for Liquid Biopsy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Circulating Biomarker for Liquid Biopsy Revenue in 2022
3.5 Circulating Biomarker for Liquid Biopsy Key Players Head office and Area Served
3.6 Key Players Circulating Biomarker for Liquid Biopsy Product Solution and Service
3.7 Date of Enter into Circulating Biomarker for Liquid Biopsy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Circulating Biomarker for Liquid Biopsy Breakdown Data by Type
4.1 Global Circulating Biomarker for Liquid Biopsy Historic Market Size by Type (2018-2023)
4.2 Global Circulating Biomarker for Liquid Biopsy Forecasted Market Size by Type (2024-2029)
5 Circulating Biomarker for Liquid Biopsy Breakdown Data by Application
5.1 Global Circulating Biomarker for Liquid Biopsy Historic Market Size by Application (2018-2023)
5.2 Global Circulating Biomarker for Liquid Biopsy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Circulating Biomarker for Liquid Biopsy Market Size (2018-2029)
6.2 North America Circulating Biomarker for Liquid Biopsy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Circulating Biomarker for Liquid Biopsy Market Size by Country (2018-2023)
6.4 North America Circulating Biomarker for Liquid Biopsy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Circulating Biomarker for Liquid Biopsy Market Size (2018-2029)
7.2 Europe Circulating Biomarker for Liquid Biopsy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Circulating Biomarker for Liquid Biopsy Market Size by Country (2018-2023)
7.4 Europe Circulating Biomarker for Liquid Biopsy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Circulating Biomarker for Liquid Biopsy Market Size (2018-2029)
8.2 Asia-Pacific Circulating Biomarker for Liquid Biopsy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Circulating Biomarker for Liquid Biopsy Market Size by Region (2018-2023)
8.4 Asia-Pacific Circulating Biomarker for Liquid Biopsy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Circulating Biomarker for Liquid Biopsy Market Size (2018-2029)
9.2 Latin America Circulating Biomarker for Liquid Biopsy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Circulating Biomarker for Liquid Biopsy Market Size by Country (2018-2023)
9.4 Latin America Circulating Biomarker for Liquid Biopsy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Circulating Biomarker for Liquid Biopsy Market Size (2018-2029)
10.2 Middle East & Africa Circulating Biomarker for Liquid Biopsy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Circulating Biomarker for Liquid Biopsy Market Size by Country (2018-2023)
10.4 Middle East & Africa Circulating Biomarker for Liquid Biopsy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Circulating Biomarker for Liquid Biopsy Introduction
11.1.4 Abbott Laboratories Revenue in Circulating Biomarker for Liquid Biopsy Business (2018-2023)
11.1.5 Abbott Laboratories Recent Development
11.2 Becton, Dickinson and Company
11.2.1 Becton, Dickinson and Company Company Detail
11.2.2 Becton, Dickinson and Company Business Overview
11.2.3 Becton, Dickinson and Company Circulating Biomarker for Liquid Biopsy Introduction
11.2.4 Becton, Dickinson and Company Revenue in Circulating Biomarker for Liquid Biopsy Business (2018-2023)
11.2.5 Becton, Dickinson and Company Recent Development
11.3 GE Healthcare
11.3.1 GE Healthcare Company Detail
11.3.2 GE Healthcare Business Overview
11.3.3 GE Healthcare Circulating Biomarker for Liquid Biopsy Introduction
11.3.4 GE Healthcare Revenue in Circulating Biomarker for Liquid Biopsy Business (2018-2023)
11.3.5 GE Healthcare Recent Development
11.4 Epigenomics AG
11.4.1 Epigenomics AG Company Detail
11.4.2 Epigenomics AG Business Overview
11.4.3 Epigenomics AG Circulating Biomarker for Liquid Biopsy Introduction
11.4.4 Epigenomics AG Revenue in Circulating Biomarker for Liquid Biopsy Business (2018-2023)
11.4.5 Epigenomics AG Recent Development
11.5 Agilent Technologies
11.5.1 Agilent Technologies Company Detail
11.5.2 Agilent Technologies Business Overview
11.5.3 Agilent Technologies Circulating Biomarker for Liquid Biopsy Introduction
11.5.4 Agilent Technologies Revenue in Circulating Biomarker for Liquid Biopsy Business (2018-2023)
11.5.5 Agilent Technologies Recent Development
11.6 Biocept
11.6.1 Biocept Company Detail
11.6.2 Biocept Business Overview
11.6.3 Biocept Circulating Biomarker for Liquid Biopsy Introduction
11.6.4 Biocept Revenue in Circulating Biomarker for Liquid Biopsy Business (2018-2023)
11.6.5 Biocept Recent Development
11.7 Affymetrix
11.7.1 Affymetrix Company Detail
11.7.2 Affymetrix Business Overview
11.7.3 Affymetrix Circulating Biomarker for Liquid Biopsy Introduction
11.7.4 Affymetrix Revenue in Circulating Biomarker for Liquid Biopsy Business (2018-2023)
11.7.5 Affymetrix Recent Development
11.8 Fluxion Biosciences
11.8.1 Fluxion Biosciences Company Detail
11.8.2 Fluxion Biosciences Business Overview
11.8.3 Fluxion Biosciences Circulating Biomarker for Liquid Biopsy Introduction
11.8.4 Fluxion Biosciences Revenue in Circulating Biomarker for Liquid Biopsy Business (2018-2023)
11.8.5 Fluxion Biosciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Abbott Laboratories
Becton, Dickinson and Company
GE Healthcare
Epigenomics AG
Agilent Technologies
Biocept
Affymetrix
Fluxion Biosciences

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂